Application of LISA technology combined with NIPPV in premature infants with mild to moderate neonatal respiratory distress syndrome

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072196

Enrollment

Unknown

Registered

2023-06-06

Start date

2023-06-05

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonatal respiratory distress syndrome

Interventions

control group:the use of lung surface active substances under traditional tracheal intubation in children who met the indications

Experimental group:the use of lung surface active substances under LISA Technology in children who met the indications

Eligibility

Sex/Gender

All

Age

No minimum to 1 Years

Inclusion criteria

Inclusion criteria: ? NIPPV for preterm infants at gestational age of 28-34 weeks, PEEP=6, FiO2 > 0.3, percutaneous oxygen saturation 60mmHg with persistent acidosis (PH < 7.2) ? Chest radiographs suggest grade I-III respiratory distress syndrome

Exclusion criteria

Exclusion criteria: Progressive dyspnea caused by severe congenital malformations (such as congenital respiratory malformations, congenital lung dysplasia, severe congenital heart disease, pulmonary hypertension, pulmonary hemorrhage, pneumothorax, diaphragmatic hernia and so on)

Design outcomes

Primary

Measure	Time frame
Incidence of bronchopulmonary dysplasia in premature infants;Incidence of intracranial hemorrhage;	—

Secondary

Measure	Time frame
Incidence of pneumothorax;Incidence of retinopathy of prematurity;	—

Countries

China

Contacts

Public ContactXiangwen Hu

Jiangxi Maternal and Child Health Hospital

381216265@163.com+86 791 8631 0568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026